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Genetics
Which Sry Locus Is the Hypertensive Y
Chromosome Locus?
Monte E. Turner, Joel Farkas, Jeff Dunmire, Daniel Ely, Amy Milsted
Abstract—The Y chromosome of the spontaneously hypertensive rat (SHR) contains a genetic component that raises blood
pressure compared with the Wistar-Kyoto (WKY) Y chromosome. This research tests the Sry gene complex as the
hypertensive component of the SHR Y chromosome. The Sry loci were sequenced in 1 strain with a hypertensive Y
chromosome (SHR/Akr) and 2 strains with a normotensive Y chromosome (SHR/Crl and WKY/Akr). Both SHR strains
have 7 Sry loci, whereas the WKY strain has 6. The 6 loci in common between SHR and WKY strains were identical
in the sequence compared (coding region, 392-bp 5 prime flanking, 1200-bp 3 flanking). Both SHR strains have a
locus (Sry3) not found in WKY rats, but this locus is different between SHR/Akr and SHR/Crl rats. Six mutations have
accumulated in Sry3 between the SHR strains, whereas the other 6 Sry loci are identical. This pattern of an SHR-specific
locus and mutation in this locus in SHR/Crl coinciding with the loss of Y chromosome hypertension is an expected
pattern if Sry3 is the Y chromosome–hypertensive component. The SHR/y strain showed a significant increase in total
Sry expression in the kidney between 4 and 15 weeks of age. There are significant differences in Sry expression between
adrenal glands and the kidney (15 to 30 times higher in kidneys) but no significant differences between strains. These
results, along with previous studies demonstrating an interaction of Sry with the tyrosine hydroxylase promoter and
increased blood pressure with exogenous Sry expression, suggest the Sry loci as the hypertensive component of the SHR
Y chromosome. (Hypertension. 2009;53[part 2]:430-435.)
Key Words: hypertension Y chromosome rats  inbred SHR genes  Sry gene copy number
Crosses between the spontaneously hypertensive rat strain(SHR) and the normotensive Wistar-Kyoto strain
(WKY) demonstrated the hypertensive effect of the SHR Y
chromosome.1 The identification of the SHR Y chromosome
influencing hypertension is analogous to the identification of
a QTL increasing blood pressure. Most techniques to identify
genes responsible for an individual QTL involve the princi-
ples of linkage and recombination.2 The unique genetics of
the mammalian Y chromosome eliminate any technique
that relies on genetic linkage and recombination to identify
the locus or loci responsible for the hypertensive pheno-
type, because the mammalian Y chromosome is present in
a single copy in males, and the majority of the chromo-
some does not undergo recombination. The properties
elucidated originally by Rapp3 for the determination of
genetic determinants of hypertension can be used to
identify and test a locus without the necessity of recom-
bination or linkage.
Physiological analysis of the SHR Y chromosome blood
pressure component is consistent with an increase in sympa-
thetic nervous system activity and stress responsiveness
associated with the increased blood pressure. We have
evaluated the Sry locus, the testis determining gene, on the Y
chromosome as a hypertension candidate gene.4 Our studies
demonstrating the interaction of Sry with the tyrosine hydrox-
ylase promoter are indicative of potential sympathetic ner-
vous system and blood pressure function for Sry in adult
males.5 In a test of this hypothesis, we electroporated an Sry
expression vector into a WKY adrenal gland and measured
blood pressure and stress responsiveness. Individuals with
exogenous Sry electroporated had significantly elevated
blood pressure and stress responsiveness 21 days after elec-
troporation.4 These results are consistent with Sry as a
hypertensive locus and a pathway of increased sympathetic
nervous system activity through increased expression of
tyrosine hydroxylase. Although these studies demonstrate a
hypertensive potential for Sry, they do not prove that Sry is
responsible for the SHR Y chromosome hypertensive
phenotype.
The Rattus norvegicus Y chromosome contains multiple
Sry loci, although theoretically only 1 copy should be
required for testis determination. We have sequenced the Sry
gene complex from a single Y chromosome from the Akron
SHR strain (SHR/Akr).6 The analysis of these sequences
identified 6 different Sry loci on the SHR Y chromosome
(Sry1, Sry2, Sry3, Sry3BI, Sry3B, and Sry3C). These are
paralogous copies consistent with a single phylogeny. Diver-
gence between any 2 copies is 2%. All 6 of the loci have a
conserved reading frame and amino acid sequence consistent
with function.
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The Sry hypertensive locus (loci) should have a pattern of
mutation and/or expression consistent with the blood pressure
phenotype in comparisons between hypertensive and normo-
tensive Y chromosomes.3 Vincent et al7 did reciprocal crosses
between SHRs and WKY rats from Charles River Laborato-
ries (SHR/Crl and WKY/Crl) and failed to find a hyperten-
sive Y chromosome effect. The original hypertensive Y
chromosome crosses and confirmations used SHR strains
originally obtained from Harlan Sprague-Dawley (SHR/Hsd
and WKY/Hsd). Thus, in a test of hypertensive Sry loci, 1
of the Sry loci in SHR/Crl will have a mutation that causes
loss of the hypertensive Y chromosome phenotype. In this
study, we compared the DNA sequences of Sry loci from
SHR/Akr, SHR/Crl, and WKY/Akr rats and expression pat-
terns from SHR/y and WKY/Akr rats. If 1 of the Sry loci
are the hypertensive locus, then mutation and expression
patterns should match the strain of origin and the hyperten-
sive phenotype.
Comparison of these strains demonstrates a Sry locus
unique to the SHR strains (Sry3) and not found in normoten-
sive strains. This locus has mutations in the SHR/Crl strain
that could change its pattern of expression, losing the hyper-
tensive potential of the SHR/Crl Y chromosome. These
results, along with the previous physiological results, are
suggestive that the Y chromosome hypertensive phenotype is
the result of the Sry loci on the SHR Y chromosome. This
gene complex fits all of the necessary criteria set forth by
Rapp3 as the genetic determinant responsible for the Y
chromosome hypertension phenotype.
Materials and Methods
Strains and Nomenclature
SHR, SHR/y, and WKY males were obtained from the University
of Akron breeding colonies (SHR/y, SHR/Akr, and WKY/Akr).
This colony was established over 20 years ago with animals
purchased from Harlan Sprague-Dawley (SHR/Hsd and WKY/
Hsd). The SHR/y strain is a Y chromosome consomic strain
developed from SHR/Akr and WKY/Akr rats. The SHR/y strain
has the SHR/Akr Y chromosome and WKY/Akr autosomes and X
chromosome. SHR males were purchased from Charles River
Laboratories USA, Wilmington, Mass (SHR/Crl). Loci from each
strain are identified with superscript strain identification. For
instance, Sry1 from SHR/Akr is designated Sry1SHR/Akr, and Sry1
from WKY/Akr is designated Sry1WKY/Akr.
Amplification and Cloning of Sry From
Genomic DNA
Primers JF-7L (TGCAGTCTCTACATTTACAATCCA) and JF-3R
(CAGAATGTGACTTCCTGTGCAT) were used to amplify
genomic DNA from each strain. Sry2 specific amplification used
JF(Sry2)-1L (CCAATGTTACCTTCTCACGGTA) and JF-3R.
Sry3A was also confirmed in strains using specific primers
JF(Sry3A)-1R (GAATGTTCCGGGAACCATTG) and JF-7L. Reac-
tions were set up using Platinum PCR SuperMix High Fidelity
(Invitrogen). The thermal cycling process consisted of 40 cycles,
each with primer annealing at 57°C and 4.5-minute extension at
72°C. PCR products were separated by electrophoresis on a 1.5%
agarose gel. On verification of the expected amplicon size, the Sry
band was cut from the gel for DNA extraction. DNA was extracted
from gel slices using the Zymoclean Gel DNA Recovery kit (Zymo
Research). To ensure efficient cloning, Sry amplicons were further
treated with Taq polymerase and 2-deoxynucleoside 5-triphosphate
mix to ensure 3 overhanging adenylation. DNA was purified using
the Zymo DNA Clean and Concentrator kit (Zymo Research).
Purified PCR product was cloned into the pCR 4-TOPO vector using
the TOPO TA Cloning Kit for Sequencing (Invitrogen). Plasmid
DNA from transformants was purified using the Zyppy Plasmid
Miniprep kit (Zymo Research).
For each strain, the process of PCR amplification, cloning, and
sequencing was carried out in multiple, independent replicates.
To avoid excessive sequencing of multiple clones of the same Sry
copy identity, clones were screened by fragment analysis to
determine copy identity.6 At least 2 clones of each copy identity,
from each PCR replicate, were selected for sequencing. Clone
sequences were assigned a copy identity by comparison with
SHR/Akr reference sequence. Clones of like copy were assembled
together using Sequencher software (GeneCodes), and the con-
sensus sequence was determined to be the sequence for that Sry
copy. The convention was adapted that, for a base difference to be
scored, it must be seen from multiple clones from different
amplification reactions.6
Sry TOPO clones were screened by fragment analysis, and clones
were selected for sequencing. Cycle sequencing reactions were set
up in 0.2-mL 96-well PCR plates, in a total volume of 10 L, using
the BigDye Terminator 3.1 Cycle Sequencing kit (Applied Biosys-
tems). The thermal cycling process consisted of 50 cycles. Samples
were loaded onto the ABI PRISM 3100 Genetic Analyzer (Applied
Biosystems) and separated by capillary electrophoresis. Sequence
data were produced using Sequencing Analysis 5.2 software (Ap-
plied Biosystems).
Real-Time PCR
Tissue collection and RNA isolation were as described previously8
from 4- and 15-week-old SHR/Y and WKY males (n4 to 5 per
group). One microgram of RNA was DNAsed and reverse tran-
scribed to cDNA using Ambion Array Script reverse transcriptase
and random nonamers for the primers. Each well of a 96-well sample
plate was set up for individual PCRs with 100 ng of cDNA, 12.5 L
of ABI SYBR Green Taq Polymerase Master Mix, and male-specific
primer sets for Sry (5-TGGGATTCTG TTGAGCCAACT-3 and
5-GCGCCCCATGAATGCAT-3) and the invariant reference tran-
script, S26 (5-CGATTCCTGACAACCTTGCTATG-3 and 5-
CGTGCTTCCCAAGCTCTATGT-3). The Sry primers detect all of
the Sry transcripts and do not discriminate among them. Controls
included no reverse transcription or reagent blanks (no template)
from each tissue sample. All of the samples were run in triplicate.
The reactions were run in the ABI Prism 7700 Real-Time PCR
System using standard parameters as specified by ABI. Transcript
levels in different samples were compared using the relative CT
method. CT values for the S26 normalizer were subtracted from CT
values for experimental samples to obtain CT values. Significance
of differences between groups was determined by ANOVA followed
by t tests, using the individual CT values.
GenBank
All of the sequences have been submitted to GenBank as follows.
SHR/Akr sequences include the following: Sry1SHR/Akr (GenBank
EU984075), Sry2SHR/Akr (FJ168057), Sry3SHR/Akr (EU984077),
Sry3ASHR/Akr (EU984078), Sry3BSHR/Akr (FJ168058), Sry3BI
SHR/Akr (FJ168059), and Sry3CSHR/Akr (EU984076). SHR/Crl
sequences include the following: Sry1SHR/Crl (FJ168060),
Sry2SHR/Crl (FJ168061), Sry3SHR/Crl (FJ168062), Sry3ASHR/Crl
(FJ168063), Sry3BSHR/Crl (FJ168064), Sry3BISHR/Crl (FJ168065),
and Sry3CSHR/Crl (FJ168066). WKY/Akr sequences include the
following: Sry1WKY/Akr (FJ168067), Sry2WKY/Akr (FJ168068),
Sry3AWKY/Akr (FJ168069), Sry3BWKY/Akr (FJ168070), Sry3BI
WKY/Akr (FJ168071), and Sry3C WKY/Akr (FJ168072).
Results
Primers used spanned the coding region and included 392
bases of 5 flanking, the entire coding region, and 1200
bases of 3 flanking. Approximately 2100 bases of contin-
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uous sequence were obtained for each copy from each
strain or isolate (392 through 1751); exact numbers
differ because of small insertion/deletion/repeat differ-
ences between copies. Amplification products were only
obtained from males; no amplification was seen in female
DNA, confirming a Y chromosome location for all of the
copies identified. Sry2 copies were found in the amplifi-
cation products from primers JF-7L and JF-3R but not in
any of the clones from any strain examined. Specific
primers unique to Sry2 and Sry3A were developed and
used to amplify genomic DNA and to determine Sry2 and
confirm Sry3A sequences. All of the strains amplified Sry2
and Sry3A with these primers. Both SHR/Akr and SHR/Crl
contain 7 Sry loci (Sry1, Sry2, Sry3, Sry3A, Sry3B,
Sry3BI, and Sry3C; Table), whereas the normotensive
WKY/Akr has only 6 Sry loci (Sry1, Sry2, Sry3A, Sry3B,
Sry3BI, and Sry3C). The Table shows the total divergence
between copies and divergence in the 5 flanking region.
Although the 5 flanking region comparisons have only
18% to 19% of the sequence compared, in some compar-
isons, such as Sry2 compared with Sry3BI, 50% of the
differences occurred in this region. The 3 flanking region
was highly conserved, and there were only 2 differences
seen in 1200 bp of flanking between any of the SHR/Akr
Sry loci, and both of these differences were in Sry1.
The Sry1, Sry2, Sry3A, Sry3B, Sry3BI, and Sry3C loci
were identical across WKY/Akr, SHR/Akr, and SHR/Crl.
The only differences found between strains were in Sry3.
Sry3 was found only in the SHR strains not in WKY rats. The
Sry3 sequences for SHR/Akr and SHR/Crl had 6 differences
between the 2 copies, and all of these differences were in the
5 flanking region. Shared differences between copies
showed that the 5 flanking region of Sry3SHR/Crl matched the
flanking region of Sry3ASHR/Crl and Sry3BISHR/Crl better than
the Sry3SHR/Akr flanking region (Figure 1).
Quantitative real-time PCR values are summarized in
Figure 2. In the WKY kidney, Sry expression was the same at
4 weeks and 15 weeks. In the SHR/y kidney, there was a
7.25-fold higher Sry expression in the 15-week adult kidney
than in the 4-week kidney (P0.03; Figure 2). At 4 weeks
and 15 weeks, the WKY and SHR/y kidney expressions were
not significantly different (4 week: P0.22; 15 week:
P0.17).
In the WKY adrenal gland, Sry expression as decreased
from 4 weeks to 15 weeks but did not reach statistical
significance (P0.059). In SHR/y, adrenal gland expression
of Sry was the same at 4 weeks and 15 weeks (not significant:
P0.88). At 4 weeks or 15 weeks, WKY and SHR/y adrenal
expressions were not different (4 weeks: P0.25; 15 weeks:
P0.08).
Sry expression varied in a tissue-specific manner. Kid-
neys expressed significantly more Sry than adrenal glands
at 15 weeks of age. In the WKY strain, Sry kidney
expression was 15.2 times the adrenal gland expression
(P0.001), and in the SHR/y strain, the kidney expression
was 31.6 times higher than adrenal gland expression
(P0.001).
Discussion
The Sry locus is an evolutionarily conserved locus on the
mammalian Y chromosome responsible for testis determi-
nation, although there is abundant evidence that this is not
its only function, because it is expressed in the brain,
kidney, and adrenal gland. Dewing et al9 showed that Sry
is expressed in substantia nigra and in T-helper– express-
ing neurons and that downregulation of Sry with antisense
oligos decreased T-helper expression in the neurons, pro-
ducing motor deficits (asymmetrical limb use). Ohe et al10
showed that SRY and SOX colocalize with splicing fac-
tors, implicating SRY in pre-mRNA splicing. In vitro DNA
binding studies have identified potential Sry target loci.
Sry binding sites and in vitro binding have been identified in a
Table. Number of DNA Sequence Mutations Between the Sry
Loci From SHR/Akr
Locus Sry1 Sry2 Sry3 Sry3A Sry3B Sry3BI Sry3C
Sry1 18 8 13 13 13 10
Sry2 8 19 22 23 23 21
Sry3 3 9 7 7 7 4
Sry3A 5 9 2 6 6 11
Sry3B 4 9 1 3 4 9
Sry3BI 5 10 2 4 1 11
Sry3C 3 9 0 2 1 2
The total numbers of differences (base pairs) between loci are above the
diagonal, and differences (base pairs) only in the 5 flanking region are below
the diagonal. Insertion/deletion/repeat differences are counted as a single
mutation. The total number of base pairs in each comparison is different
because of insertion/deletion/repeat mutations between the loci.
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Figure 1. Shared differences between Sry loci in the 5 flanking
region. Single base-pair differences are indicated as like Sry1
(white) or different from Sry1 (gray). Mutations unique to an indi-
vidual locus are not illustrated in A. Base-pair numbering is in
relation to the first base of coding region as bp 1, and negative
base-pair numbers indicate 5 flanking the coding region. A, Sry
loci from SHR/Akr. B, Comparison of Sry3 from SHR/Akr and
SHR/Crl.
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number of genes: P450 aromatase, antimu¨llerian hormone
(AMH), Fra-1, and Fra-2.11,12 Although the P450 aromatase and
AMH are known components of mammalian sex determination,
the Fra-1 and Fra-2 loci are components of transcription factor
activator protein-1.13 We have demonstrated that Sry1 expres-
sion increases activity of the tyrosine hydroxylase promoter
consistent with a potential sympathetic nervous system blood
pressure affect.4 These results indicate that Sry has the
potential to be more than just the testis-determining factor.
Any cell or tissue expressing Sry expressed could demon-
strate altered transcriptional regulation of Sry/SOX-
controlled loci, because Sry and SOX loci have the same
consensus-binding site.14
All of the Sry loci sequenced from these strains have a
full-length, potentially active coding region, based on
conserved regions identified from previous sequencing
results.6 We had previously identified 6 Sry loci in the SHR/Akr
strain,6 and these results show 7 loci from the same strain. The
Sry3 and Sry3A loci identified in the current data were
cryptic, and only by using primers that amplified a larger
region than previous results could these loci be differen-
tiated, changing the number present from 6 to 7. The
sequence differences between the different Sry loci within
the SHR/Akr strain are 1%, although the 5 flanking
region has much higher divergence in some comparisons
(Table). Sry2 is the most divergent copy and the most
common transcript in the testis and adrenal.6 The DNA
sequence differences in any particular copy between the
strains are virtually nonexistent; the only differences seen
in any copy between strains are in Sry3 between SHR/Akr
and SHR/Crl.
The Rapp paradigm3 requires 4 criteria to identify genes
that cause differences in blood pressure: (1) a difference
between strains; (2) a mendelian inheritance pattern; (3) a
cosegregatation of genes with blood pressure increment; and
(4) a logical physiological link to blood pressure. Crosses
between the SHR strain and the normotensive WKY strain
demonstrated the hypertensive effect of the SHR Y chromo-
some.1 Other crosses with SHR substrains and other normo-
tensive strains confirmed this conclusion.15 The development
of strains consomic for the SHR and WKY Y chromosomes
demonstrates the expected blood pressure for a Y chromo-
some hypertensive locus.16
The Sry loci have been examined as candidate hyperten-
sive loci from the Y chromosome. Experiments in cell culture
demonstrated that Sry expression could increase transcrip-
tional activity of the tyrosine hydroxylase promoter consis-
tent with the sympathetic nervous system activation seen
associated with Y chromosome hypertension.5 Electropora-
tion of Sry expression vectors into the adrenal gland tran-
siently increased blood pressure in normotensive animals.4
These results indicated that the Sry loci could be responsible
for increased blood pressure, and Sry could affect a known
physiological pathway of blood pressure control in appropri-
ate tissues (tyrosine hydroxylase in the sympathetic nervous
system). A mutation analysis in hypertensive and normoten-
sive strains is needed to confirm the Sry hypertensive locus
hypothesis.
The current data demonstrate a Sry copy number varia-
tion between the SHR and WKY strains. This is consistent
with the Sry gene complex as the hypertensive component
of the SHR Y chromosome. The 6 Sry loci that are found
in both SHR and WKY strains have no differences between
the strains in a total of 13 kb compared. The comparison
between Sry loci in SHR/Akr and SHR/Crl is important in
confirming Sry as the hypertensive locus. If the Sry gene
complex were identical in SHR/Akr and SHR/Crl strains,
the Sry gene complex would be eliminated as the Y
chromosome hypertensive component. The SHR/Crl iso-
late has the same copy number variation as the SHR/Akr
strain but does not have a Y chromosome that increases
blood pressure. Thus, the presenceof the additional copy
alone cannot be responsible for the hypertensive phenotype.
Consistent with the SHR-to-WKY comparison, for the 6 loci
found in all of the SHR and WKY strains, there are no
differences between SHR/Akr and SHR/Crl. The Sry3 locus,
which is the unique copy in the SHR strains, has 6 differences
between SHR/Akr and SHR/Crl (Figure 1). The loss of hyper-
tensive potential is associated with a mutant copy of the
SHR-specific Sry locus, whereas all of the other Sry loci are
identical. The loss of the hypertensive potential is most likely
the result of expression differences between SHR/Akr and
SHR/Crl, because all of the identified differences are in the
area 5 to the coding region of the gene. This pattern of Sry
differences, first copy number variation between SHR and
WKY and second mutations between SHR/Akr and SHR/Crl,
is a predicted pattern if the Sry gene complex is responsible
for the hypertensive Y chromosome. The chance of this
pattern of mutation occurring between SHR/Akr and SHR/Crl
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Figure 2. A, Total Sry expression varies with tis-
sue; 15-week SHR/y kidneys express 31.60	1.78
times more Sry than SHR/y adrenal glands. In
WKY kidneys, Sry levels are 15.20	1.55 times
higher than in WKY adrenal glands. *P0.001, kid-
ney vs adrenal gland. Strain differences are not
significant. Values for SHR/y adrenal gland were
set equal to 1, and all other values compared with
them. B, Total Sry expression in the SHR/y kidney
increases with age. Sry levels are 7.25	2.75 times
higher in the 15-week samples. *P0.03. Values
for 4 weeks were set equal to 1, and values for 15
weeks were compared with them.
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occurring randomly would be extremely small, because there
are no other differences observed between the other Sry loci.
A hypertensive Sry would need to be expressed in appro-
priate tissues, such as the kidney and adrenal gland, and
potentially differs between SHR and WKY strains. The
quantitative real-time PCR values for Sry expression use
primers that amplify all of the copies. Thus, the measured
values are total Sry expression without regard to copy
identity. Expression levels are significantly different between
the kidney and adrenal gland, with significantly higher levels
in the kidney than in the adrenal gland (Figure 2). Although
there are no significant differences between the strains, there
is a significant difference between 4-week and 15-week
SHR/y. There is 7 times more expression in the 15-week
SHR/y kidney than in the 4-week SHR/y kidney. In SHR/y,
Sry expression is increasing at the same time that blood
pressure is increasing. We do not see the same significance in
the WKY rats. This may be because of the timing of a
developmental change in expression and the exact timing of
the switch. Consistent with this idea is the observation that
the developmental timing of testosterone production during
puberty is slightly but significantly earlier in SHRs than
WKY rats.17 The expression results are not as conclusive as
the mutation analysis but do not exclude Sry as a hyperten-
sive locus. We do not have a complete copy-specific expres-
sion profile that may clarify the hypertensive expression
pattern and mechanism. We also have not completely ex-
cluded the possibility of additional Y chromosome compo-
nents contributing to Y chromosome hypertension.
What is the genetic mechanism of the Sry gene complex
and hypertension? The Sry1 locus has been demonstrated
to have hypertensive potential. The Sry1 and Sry3 pre-
dicted amino acid sequences have only 2 amino acids
different and only 1 in the 3-hydroxy-3-methylglutaryl box
(amino acids 5 to 73) responsible for binding DNA. The
Sry3 locus has a glutamine at amino acid 37 and Sry1, a
histidine.6 The Sry3 locus has a mutational pattern consis-
tent with the phenotype of hypertensive and normotensive
Y chromosomes. The expression data of Sry are at only 2
time points and not copy specific. It is possible that the
expression of multiple Sry loci is able to increase blood
pressure in a quantitative threshold model, where the
expression of multiple Sry loci has an additive effect, and
blood pressure is elevated only after a certain threshold
level of expression is reached. The extra Sry3 locus on the
hypertensive Y chromosomes increases the Sry activity
over some threshold value. The mutant flanking region of the
Sry3SHR/Crl locus changes its expression pattern, reducing the
Sry activity in tissues responsible for hypertension.
Sry is a transcription factor, and, as such, the Sry protein
does not directly increase blood pressure but changes the
expression pattern of target loci, which then cause an increase
in blood pressure. Regardless of the exact mechanism for the
differences observed, it is extremely improbable that the
pattern seen for the hypertension phenotypes and Sry DNA
sequence differences are unrelated. In conclusion, the Sry loci
fit the criteria elucidated by Rapp3 for determining a hyper-
tensive locus. Although the exact mechanism or mechanisms
for the increase is not known, the data are consistent with Sry
as the loci responsible and the SHR/Akr Sry3 locus as the
difference between the hypertensive and nonhypertensive Y
chromosomes.
Perspectives
In human populations, different Y chromosomes have been
demonstrated to be significantly different in hypertensive and
normotensive comparisons.18,19 The human Y chromosome
has only a single copy of the SRY locus, although mutant
human Y chromosomes have been identified with multiple
copies of SRY.20 The 3-hydroxy-3-methylglutaryl box of all
mammalian Sry loci is highly conserved, and in vitro Sry and
the related Sox loci all bind to the same DNA response
sequences.14 The rat Sry loci can probably control many of
the same loci as the human SRY locus. Any proposed
mechanism for the hypertensive potential of human SRY
does not rely only on multiple copies, but the expression of
SRY in tissues of hypertensive potential turning on loci,
which increases blood pressure. A mutation in human SRY
that would cause or increase expression in an appropriate
tissue (adrenal or kidney) could result in increased blood
pressure. In a human hypertensive Y chromosome, the SRY
expression mutation must not eliminate wild-type SRY ex-
pression but add to the normal expression pattern. Informa-
tion on mutant human SRY loci is limited to individuals
without normal testis determination capabilities. There is no
study of normal variation for functional human SRY loci.
Having multiple copies of Sry, as in R norvegicus, may
increase the opportunity for Sry expression differences caus-
ing hypertension, because other loci can maintain wild-type
Sry expression.
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